US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Militia Long/Short Equity ETF

29.26

-0.2400-0.81%

Volume:12.99K

Turnover:381.38K

Market Cap:- -

PE:- -

High:29.63

Open:29.33

Low:29.26

Close:29.50

Loading ...

Overview Company News Filings

Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update

Press Release: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update

Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer

Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update

New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer

Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer

PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS

MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/ORR/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":29.26,"timestamp":1751305734699,"preClose":29.5,"halted":0,"volume":12993,"delay":0,"floatShares":2870000,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.24,"latestTime":"06-30 13:49:52 EDT","open":29.3301,"high":29.63,"low":29.26,"amount":381376.499787,"amplitude":0.012542,"askPrice":29.33,"askSize":2800,"bidPrice":29.18,"bidSize":900,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1751313600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":29.5,"sharesOutstanding":2870000,"nav":29.02,"aum":83287400,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.5,"preClose":29.5,"latestTime":"16:00 EDT","volume":15,"amount":442.5,"timestamp":1751054402295},"volumeRatio":0.772173},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":2870000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.772173,"shares":0,"dividePrice":0,"high":29.63,"amplitude":0.012542,"preClose":29.5,"low":29.26,"week52Low":25.63,"pbRate":"--","week52High":29.71,"institutionHeld":0,"latestPrice":29.26,"committee":-0.513514,"eps":0,"divideRate":0,"volume":12993,"delay":0,"ttmEps":0,"open":29.3301,"prevYearClose":25.88,"prevWeekClose":29.5,"prevMonthClose":28.1031,"prevQuarterClose":27.84,"fiveDayClose":28.7113,"twentyDayClose":28.1031,"sixtyDayClose":27.76},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2514358517","title":"Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514358517","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514358517?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:10","pubTimestamp":1740690600,"startTime":"0","endTime":"0","summary":"- Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L PD-L1+ r/m HNSCC and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling; expected to be substantially ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/27/3034341/37568/en/Merus-Announces-Financial-Results-for-the-Fourth-Quarter-and-Full-Year-2024-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR"],"gpt_icon":0},{"id":"2514303073","title":"Press Release: Cardiff Oncology Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514303073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514303073?lang=en_us&edition=fundamental","pubTime":"2025-02-28 05:05","pubTimestamp":1740690300,"startTime":"0","endTime":"0","summary":"- Robust initial efficacy signal with onvansertib + chemo/bev in ongoing first-line RAS-mut metastatic colorectal cancer  clinical trial  -. - Priced oversubscribed $40 million underwritten registered direct offering with participation from new and existing healthcare dedicated investors -. - Issuance of new patent with claims for the use of onvansertib for treating KRAS-mut mCRC -. - Cash and equivalents of $91.7 million as of December 31, 2024, projected runway into Q1 2027 -. - Company will hold a conference call today at 4:30 p.m. ET/1:30 p.m. PT -. SAN DIEGO, Feb. 27, 2025  -- Cardiff Oncology, Inc. , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.-- Additional clinical data from CRDF-004 trial expected in 1H 2025. Company highlights for the quarter ended December 31, 2024, and subseq","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","CRDF","BK4139","PDX"],"gpt_icon":0},{"id":"2514896706","title":"Press Release: Mesoblast Sets Ryoncil(R) Price Based on Economic Value of Treatment With Planned Product Availability This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2514896706","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514896706?lang=en_us&edition=fundamental","pubTime":"2025-02-27 06:30","pubTimestamp":1740609000,"startTime":"0","endTime":"0","summary":"Mesoblast Sets Ryoncil Price Based on Economic Value of Treatment With Planned Product Availability This Quarter. Financial Results and Operational Update for Half-Year Ended December 31, 2024. NEW YORK, Feb. 26, 2025  -- Mesoblast Limited , global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended December 31, 2024,\"Our FDA approved product Ryoncil will be available in the coming weeks to the children with SR-aGvHD in need of life-saving therapy,\" said Dr. Silviu Itescu, Chief Executive of Mesoblast. \"The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S.\". Ryoncil  U.S. Launch for Steroid-Refractory Acute Graft Versus Host Disease. FDA approved Ryoncil as the first and only therapy for pediat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MMAT","MSB.AU","BK4099","ORR","BK4150","BK4183","BK4555","BK4551","CD","BK4022","BK4232","IBD","BK7067","BK7501","03160","WAC","BK4161","BK4546","DDD","BK4575","BK4139","BK4588","MSC","BK4585","BK4170","BK4116","BK4604","MESO","BK7508","TM","BK4141","R","ODD"],"gpt_icon":1},{"id":"2514895520","title":"Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications","url":"https://stock-news.laohu8.com/highlight/detail?id=2514895520","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514895520?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:48","pubTimestamp":1740606480,"startTime":"0","endTime":"0","summary":"LEXINGTON, Mass., February 26, 2025----Agenus Inc. , a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.Agenus is advancing a robust clinical pipeline targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, tumor microenvironment conditioning agents and cell therapies . Our most advanced antibody candidates, botensilimab  an Fc-enhanced CTLA-4 blocking antibody, and balstilimab , a novel, PD-1 inhibitor, are central to our efforts.BOT is currently being investigated as a monotherapy and in combination with widely used standard of care anti-PD-1, chemotherapy, and allogeneic cell therapy across multiple indications:. Dr. O’Day continues, \"By leveraging our deep expertise in immune activation, we are unlocking responses in tumors previously resistant to immunotherapy. The results are even more promising as we move from treatment refractory me","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agenus-reports-impact-key-immuno-214800977.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BK4113","AGEN","BK4139","MSS","BK4232","LU0456854461.SGD","LU0266512127.USD","OS","BAL","BK4211","BK4022","BK4195","BK4213","CRC","PFS","BK4097","R"],"gpt_icon":0},{"id":"2514898618","title":"Relay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514898618","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514898618?lang=en_us&edition=fundamental","pubTime":"2025-02-27 05:05","pubTimestamp":1740603900,"startTime":"0","endTime":"0","summary":"Initiation of Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant anticipated in the middle of 2025 in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- metastatic breast cancer. Continued progression of other front-line breast cancer regimens, including initiation of atirmociclib triplet, and planning for development of future oral endocrine therapy combinations underway. Approximately $780 million in cash, cash equivalents and investments at end of Q4 2024, which will be prioritized to fully fund the execution of the ReDiscover-2 Phase 3 trial. CAMBRIDGE, Mass., Feb. 26, 2025  -- Relay Therapeutics, Inc. , a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported fourth quarter and full year 2024 financial results and corporate highlights.Relay Tx has conducted an end of Phase 2 meeting with the Food and Drug Administration  and announces the Phase 3 trial design, dose, and pla","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relay-therapeutics-reports-fourth-quarter-210500946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BK4211","RLAY","BK4195","PFS","BK4139","BK4563"],"gpt_icon":0},{"id":"2514853387","title":"MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2514853387","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514853387?lang=en_us&edition=fundamental","pubTime":"2025-02-26 21:47","pubTimestamp":1740577620,"startTime":"0","endTime":"0","summary":"Expansion study to enroll patients in the U.S. and select countries in Europe and Asia. CHICAGO, February 26, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the trial design for the expansion of its THIO-101 pivotal Phase 2 trial in non-small cell lung cancer . Following successful outcomes to date in THIO-101, the expansion of the study will assess overall response rates  in advanced NSCLC patients receiving third line  therapy who were resistant to previous checkpoint inhibitor treatments  and chemotherapy.MAIA recently announced an amended clinical supply agreement with Regeneron to include the expansion portion of THIO-101. Under terms of the amended agreement, MAIA continues to sponsor THIO-101 and Regeneron will provide Libtayo for the treatment of all patients including the additional patients in the expansion and potentially, the registration studies.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-design-expansion-134700870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["L","MAIA","BK4196","OS","LU1261432733.SGD","AEIS","BK4585","IE00B19Z3581.USD","LU0289739699.SGD","IE00B19Z4B17.USD","IE00B19Z3B42.SGD","CI","CPI","LU0053666078.USD","LU0058720904.USD","IE0031619046.USD","LU1059921491.USD","BK4157","BK4107","BK4588","IE00B7SZL793.SGD","BK4097","IE0002270589.USD","BK4139","LU0868494617.USD","ORR","IE00BSNM7G36.USD","IE00B66KJ199.SGD"],"gpt_icon":0},{"id":"2514983992","title":"Immunocore reports fourth quarter and full year 2024 financial results and provides a business update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514983992","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514983992?lang=en_us&edition=fundamental","pubTime":"2025-02-26 20:00","pubTimestamp":1740571200,"startTime":"0","endTime":"0","summary":"KIMMTRAK  Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025. Executing on KIMMTRAK lifecycle management with two Phase 3 trials  in additional melanoma indications. Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C . First patient dosed in Phase 1/2 trial of IMC-R117C  in colorectal and other gastrointestinal cancers. CTA/IND on track for IMC-S118AI  in 2H 2025 and for IMC-U120AI, our first non-HLA-restricted candidate initially for atopic dermatitis, in 2026. Cash, cash equivalents and marketable securities of $820.4 million as of December 31, 2024. “In 2024, we continued to grow KIMMTRAK sales, execute on our KIMMTRAK lifecycle management program, advance our deep clinical pipeline, and expand into autoimmune diseases, supported by a strong cash position and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunocore-reports-fourth-quarter-full-120000489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MTD","BK4599","LU2413666699.HKD","BK4097","IE00BYQQ9H92.USD","LU1721428933.USD","ALT","CM","BK4147","ATOM","BK4006","LU1878469433.USD","BK4207","LU1093756168.USD","PROC","BK4211","BK4195","BK4007","IE00B7SZL793.SGD","BK4139","IMCR","LU2413666426.HKD","BK4533","BK4585","CTA","IE00B66KJ199.SGD","CRS","BK4505","BK4588","IE0031619046.USD","PFS","BK4567","LU1093756325.SGD","OS","LU2065731478.USD","ORR","BK4548","IE00BFXG0V08.USD","BK4121","IE00B19Z4B17.USD","LU0347712357.USD"],"gpt_icon":0},{"id":"2514044305","title":"Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2514044305","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514044305?lang=en_us&edition=fundamental","pubTime":"2025-02-26 05:05","pubTimestamp":1740517500,"startTime":"0","endTime":"0","summary":"New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate  and progression-free survival  relative to published data from studies with HIF-2a inhibitors to date. Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in immuno-oncology -experienced patients with clear cell renal cell carcinoma  is expected in the first half of 2025; initial data from the cohort of ARC-20 evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025. Arcus completed a $150 million financing and continues to be well positioned to advance its pipeline with $992 million in cash, cash equivalents and marketable securities as of December 31, 2024 . HAYWARD, Calif., February 25, 2025----Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcus-biosciences-reports-fourth-quarter-210500045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCUS","BK4139","PFS","BK4195","BK4211","ORR"],"gpt_icon":0},{"id":"2514093462","title":"Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2514093462","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514093462?lang=en_us&edition=fundamental","pubTime":"2025-02-25 20:00","pubTimestamp":1740484800,"startTime":"0","endTime":"0","summary":"Updated topline Phase 1 combination data for zelenectide pevedotin plus pembrolizumab continue to show promising anti-tumor activity and a differentiated safety profile in first-line metastatic urothelial cancer; Duravelo-2 dose selection data expected in 2H 2025. Enhanced response to zelenectide pevedotin seen in NECTIN4 gene-amplified late-line breast cancer and non-small cell lung cancer , resulting in U.S. FDA Fast Track designations for triple-negative breast cancer and NSCLC; several Phase 1/2 trials expected to start in 2025. Cash and cash equivalents of $879.5 million as of December 31, 2024, expected to provide financial runway into 2H 2027. CAMBRIDGE, England & BOSTON, February 25, 2025----Bicycle Therapeutics plc , a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide  technology, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided recent corporate u","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bicycle-therapeutics-reports-recent-business-120000723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","ORR","BK4139","PIPE","PRGS","BK4097","LU2065732104.USD","BCYC"],"gpt_icon":0},{"id":"2512432823","title":"Bristol Myers Cancer Drug Opdivo In Combination With Chemo Shows Improved Overall Survival In Certain Patients With Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512432823","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512432823?lang=en_us&edition=fundamental","pubTime":"2025-02-20 05:14","pubTimestamp":1739999669,"startTime":"0","endTime":"0","summary":"On Wednesday, Bristol Myers Squibb& Co  announced the final analysis of overall survival  from the Phase 3 CheckMate -816 study, which evaluatedOpdivo  in combination with platinum-doublet chemotherapy as a neoadjuvant treatment for adult patients with resectable non-small cell lung cancer .Also Read: Trump’s Tax Cut Could Add $4.6 Trillion To Deficit, With $48 Billion Tax Relief For Top 100 Firms: Robert Reich. The results showed a statistically significant and clinically meaningful improvement in overall survival, a key secondary endpoint, compared to neoadjuvant chemotherapy alone.The results build on the previously reported primary endpoints of event-free survival  and pathological complete response , which also met statistical significance.The safety profile ofOpdivoin combination with chemotherapy was consistent with previously reported studies, with no new safety signals observed.Price Action: BMY stock closed higher by 1.01% to $54.98 on Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bristol-myers-cancer-drug-opdivo-211429682.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","LU2125154778.USD","LU1430594728.SGD","LU1670711040.USD","IE0002141913.USD","BK4559","LU0061475181.USD","LU0985481810.HKD","ORR","LU0096364046.USD","LU0321505868.SGD","LU1074936037.SGD","LU0306807586.USD","BK4126","LU1718418525.SGD","LU2133065610.SGD","LU1291159041.SGD","ALK","LU1868836591.USD","LU1868836914.USD","LU0321505439.SGD","BK4008","IE00BSNM7G36.USD","LU1868837300.USD","BMY","LU2125154935.USD","IE00BJJMRZ35.SGD","LU0225771236.USD","LU1670710661.SGD","LU1032466523.USD","LU2242652126.USD","IE00BFTCPJ56.SGD","LU1585245621.USD","LU1261432733.SGD","IE0009355771.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0306806265.USD","LU0868494617.USD","LU1670710588.SGD","LU1670711123.USD","LU1093756325.SGD","BK4500","LU0225284248.USD","BK4585","LU1093756168.USD","LU1868836757.USD","MYE","LU1989771016.USD","LU1323610961.USD"],"gpt_icon":0},{"id":"2512197636","title":"Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2512197636","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512197636?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:00","pubTimestamp":1739880000,"startTime":"0","endTime":"0","summary":"Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential ofpelareorep across very different tumor types. \"We're hitting critical milestones that validate our progress and set the stage for what we believe will be an exciting year,\" said Wayne Pisano, Interim CEO and Chair of Oncolytics' Board of Directors. \"With positive feedback from regulators in place, we're advancing our pancreatic cancer study toward full enrollment, and our ASCO GI presentations highlighted pelareorep's strong safety and efficacy results in two hard-to-treat cancers. We remain focused on bringing new treatment options to patients while creating value for shareholders as we move forward in 2025.\". German Regulatory Agency Gives Green Light for Pancreatic Cancer Study to Continue as Planned. Approval to Fully Enroll the Cohort Secured: Germany's Paul-Ehrlich-Institute  has given Oncolytics the go-ahead to continue enro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/oncolytics-biotech-strengthens-pipeline-2025-120000696.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/oncolytics-biotech-strengthens-pipeline-2025-120000696.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ORR","BK4139","AIO","ONCY"],"gpt_icon":0},{"id":"2512159344","title":"Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2512159344","media":"Business Wire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512159344?lang=en_us&edition=fundamental","pubTime":"2025-02-18 19:57","pubTimestamp":1739879820,"startTime":"0","endTime":"0","summary":"Gilead Sciences’ window to exercise its option to casdatifan has expired; $150 million financing enables Arcus to independently advance its development program for casdatifan. New data from the ARC-20 study in patients with clear cell renal cell carcinoma  showed that casdatifan monotherapy demonstrated improvements in the rate of primary progression, overall response rate  and progression-free survival  and reinforced its differentiation relative to published data from studies with HIF-2a inhibitors to date. Arcus will host a conference call today to discuss the ARC-20 results and casdatifan development plans at 5:00 AM PT / 8:00 AM ET. The new data from ARC-20, a Phase 1/1b study of the HIF-2a inhibitor casdatifan in ccRCC, were presented in a rapid oral session at the 2025 American Society of Clinical Oncology  Genitourinary  Cancers Symposium by Dr. Toni Choueiri, Dana-Farber Cancer Institute. The presentation included ORR for the 50mg twice-daily  cohort, 50mg o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcus-biosciences-retains-rights-casdatifan-115700300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4179","ORR","PFS","IO","BK4195","QD","BK4211","BK4166","BK4503","RCUS","BK4563"],"gpt_icon":0},{"id":"2511860458","title":"New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2511860458","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511860458?lang=en_us&edition=fundamental","pubTime":"2025-02-16 04:45","pubTimestamp":1739652300,"startTime":"0","endTime":"0","summary":"A 9.7-month median progression-free survival  was reached for the 50mg twice-daily  casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other cohorts. Across all three monotherapy cohorts presented, casdatifan demonstrated improvements in the rate of primary progression, overall response rate  and progression-free survival  relative to published data from studies with HIF-2a inhibitors to date. Arcus will host a conference call to discuss these data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025. \"The newest data are from the 100mg cohort using the tablet formulation and the expected go-forward dose for pivotal studies, which showed a 33% confirmed response rate despite the relatively short follow-up,\" said Richard Markus, M.D., Ph.D., chief medical officer at Arcus Biosciences. \"Casdatifan continues to be well tolerated, with a very low discontinuation rate, supporting its strong potential in combination therapy. We look forward to shar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-demonstrated-best-class-potential-204500902.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RCUS","PFS","BK4166","BK4139","BK4563","BK4195","BK4211","IO","ORR","QD","BK4179","BK4503"],"gpt_icon":0},{"id":"2511085575","title":"Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2511085575","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511085575?lang=en_us&edition=fundamental","pubTime":"2025-02-14 05:30","pubTimestamp":1739482200,"startTime":"0","endTime":"0","summary":"Efficacy Comparable to Approved Autologous CD19 CAR Ts:Achieved Overall Response  and Complete Response  Rates of 58% and 42% Across the Study and 67% and 58% with Pivotal Study Regimen, Respectively. Durability of Response:Among Patients Who Achieved CR, Median Duration of Response  of 23.1 Months and Median Overall Survival  Not Reached. Foundation for Cema-Cel in ALPHA3 Trial in First Line  Consolidation: Achieved 100% CR in Patients with Low Disease Burden. \"With multiple patients in ongoing complete remissions beyond four years, the lingering question of whether an allogeneic CAR T could deliver durable responses has now been answered,\" said Zachary Roberts, M.D., Ph.D., Executive Vice President, Research and Development and Chief Medical Officer of Allogene. \"Furthermore, these results provide potent evidence supporting the use of CAR T in patients with low disease burden and the unique opportunity for the ALPHA3 trial to achieve something novel in this disease – predict and inte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/allogene-therapeutics-announces-publication-durable-213000140.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","CAR","BK4097","ORR","IE00B66KJ199.SGD","BK4022","CR","SOC","BK4213","ALLO","BK4139","BK4230","IE0031619046.USD","BK4505","CRS","BK4161","LU2065731478.USD","IE00B19Z4B17.USD","OS","BK4006"],"gpt_icon":0},{"id":"2511710925","title":"Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2511710925","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511710925?lang=en_us&edition=fundamental","pubTime":"2025-02-14 02:02","pubTimestamp":1739469720,"startTime":"0","endTime":"0","summary":"It was a busy week for the biotech sector, as the fourth-quarter earnings season is in full swing. While Gilead Sciences, Inc. GILD gained following the earnings beat and upbeat guidance for 2025, Biogen BIIB was in the red as the annual guidance disappointed investors. Meanwhile, other pipeline and regulatory updates were also in focus.Gilead Sciences reported better-than-expected fourth-quarter results and provided an upbeat guidance for 2025. Shares of the company gained 7.5% following the same. Adjusted earnings per share  of $1.90 beat the Zacks Consensus Estimate of $1.67. In the year-ago quarter, the company reported EPS of $1.72.Total revenues of $7.6 billion comfortably beat the Zacks Consensus Estimate of $7.1 billion. Revenues also increased 6% year over year, primarily due to higher HIV, oncology and liver disease drug sales. Flagship HIV therapy Biktarvy’s sales increased 21% year over year to $3.8 billion, driven by higher demand, favorable inventory dynamics and higher a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-gild-q4-180200974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BIIB","LU0098860793.USD","LU0061475181.USD","BK4578","IE00BZ1G4Q59.USD","LU1989771016.USD","LU0314104364.USD","LU0058720904.USD","GILD","LU2468319806.SGD","SWTX","LU1732799900.SGD","LU0106831901.USD","LU1585245621.USD","LU1989772923.USD","LU0225284248.USD","LU1868837136.USD","LU1670710661.SGD","BK4588","LU1032466523.USD","LU1291159041.SGD","BK4566","IE00B19Z9P08.USD","IE00BJT1NW94.SGD","LU0225283273.USD","LU2089283258.USD","LU1989772840.SGD","LU1839511570.USD","BK4559","LU1548497426.USD","LU0289739699.SGD","LU2347655156.SGD","BK4516","IE0002141913.USD","BMY","LU2087621335.USD","IE00B7SZLL34.SGD","LU1868837300.USD","LU1868836757.USD","IE00B19Z3B42.SGD","LU0882574055.USD","LU0971096721.USD","BK4504","ORR","LU1720051017.SGD","LU1868836914.USD","LU0456855351.SGD","LU0795875169.SGD","LU0321505439.SGD"],"gpt_icon":0},{"id":"2511580714","title":"Galapagos Reports Full Year 2024 Results and Provides Fourth Quarter Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2511580714","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511580714?lang=en_us&edition=fundamental","pubTime":"2025-02-13 05:01","pubTimestamp":1739394060,"startTime":"0","endTime":"0","summary":"Compelling clinical results for GLPG5101 in three NHL indications underscore potential of innovative decentralized cell therapy platform to deliver fresh, fit cells, in median seven days vein-to-vein. Focusing on accelerating GLPG5101 program, expanding to eight indications with significant unmet needs, and aiming for first approval by 2028. Plan to separate into two companies listed on Nasdaq and Euronext, with SpinCo to build a pipeline through deals and Galapagos to advance novel cell therapies for cancers of high unmet need. Management to host conference call tomorrow, February 13, 2025, at 14:00 CET / 8:00 am ET. Mechelen, Belgium; February 12, 2025, 22:01 CET; regulated information – GalapagosNV , a global biotechnology company dedicated to transforming patient outcomes through life-changing science and innovation, today reported its financial results for the full year 2024 and provided an update on the fourth quarter 2024 and its year-to-date performance.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/galapagos-reports-full-2024-results-210100294.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4077","LU0757428866.USD","BK4546","BK4161","BK4094","BK4139","FL","GLPG","LU1815336091.USD","ORR","SLE","BK4023","BK4585","BK4588","DM","BL"],"gpt_icon":0},{"id":"2509521222","title":"New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509521222","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509521222?lang=en_us&edition=fundamental","pubTime":"2025-02-06 06:00","pubTimestamp":1738792800,"startTime":"0","endTime":"0","summary":"UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025  -- Merus N.V.  , a clinical-stage oncology company developing innovative, full-length multispecific antibodies , today announced that the New England Journal of Medicine  published results of the registrational phase 2 eNRGy trial for Bizengri , the first and only treatment indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer  that are advanced unresectable or metastatic and harbor a neuregulin 1  gene fusion who have disease progression on or after prior systemic therapy.BIZENGRI is indicated for adults with pancreatic adenocarcinoma or non–small cell lung cancer  that are advanced unresectable or metastatic and harbor a neuregulin 1  gene fusion who have disease progression on or after prior systemic therapy. These indications are approved under accelerated approval based on overall response rate  and duration of response . Continued approval for these indication","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/england-journal-medicine-publishes-efficacy-220000426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0109394709.USD","BK4139","MRUS","LU0320765992.SGD","ORR","LU0889565916.HKD"],"gpt_icon":0},{"id":"2509285305","title":"Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2509285305","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509285305?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"The ACR-368-tailored OncoSignature assay is being used to predict patients most likely to respond to ACR-368 in Acrivon’s ongoing, registrational-intent, multicenter Phase 2b trial of ACR-368 in patie","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021122/0/en/Acrivon-Therapeutics-Announces-FDA-has-Granted-Breakthrough-Device-Designation-for-ACR-368-OncoSignature-Assay-for-Endometrial-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ACR","LENZ","ORR","BK4110","BK4139"],"gpt_icon":0},{"id":"2509466090","title":"PFE's Colorectal Cancer Drug Meets Other Dual Primary Goal of PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2509466090","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509466090?lang=en_us&edition=fundamental","pubTime":"2025-02-04 22:26","pubTimestamp":1738679160,"startTime":"0","endTime":"0","summary":"PfizerPFE announced positive top-line results from the progression-free survival  analysis of a late-stage study of its oncology drug, Braftovi , for treating patients with metastatic colorectal cancer  harboring a BRAF V600E mutation. Braftovi is an oral small-molecule kinase inhibitor that targetsBRAF V600E.The phase III BREAKWATER study is evaluating the candidate's safety and efficacy in combination with Eli Lilly’s LLY Erbitux  and chemotherapy  in mCRC patients harboring a BRAF V600E mutation.BRAF mutations are found in 8-12% of mCRC cases and are linked to a poorer prognosis. The BRAF V600E mutation is the most common and more than doubles the risk of death compared to patients without any mutation. Despite the high unmet need, no biomarker-driven therapies were approved for previously untreated BRAF V600E-mutant mCRC until December 2024. Thus, Pfizer has the first-mover advantage in t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pfes-colorectal-cancer-drug-meets-142600063.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1066053197.SGD","LU0882574055.USD","LLY","LU1023059063.AUD","LU2237443895.HKD","CSTL","LU0114720955.EUR","LU1623119135.USD","LU1127390331.HKD","LU2361044865.SGD","LU0306806265.USD","ORR","BK4007","LU1894683264.USD","IE0002141913.USD","BK4534","BK4588","LU2491049909.HKD","LU1093756325.SGD","LU2361044949.HKD","LU1720051017.SGD","PFS","LU0238689110.USD","LU0823416689.USD","BK4516","PFE","LU1868836757.USD","LU1064131342.USD","LU0079474960.USD","LU0354030438.USD","LU2237438978.USD","LU0097036916.USD","LU2361045086.USD","LU2106854487.HKD","BK4581","IE00BK4W5M84.HKD","IE00B19Z3B42.SGD","LU1280957306.USD","ALNY","LU0170899867.USD","LU0640476718.USD","SG9999002232.USD","LU2324357040.USD","LU0868494617.USD","LU2491050154.USD","SGXZ99366536.SGD","LU1291159041.SGD","LU0471298694.HKD","IE00BBT3K403.USD","LU1066051498.USD"],"gpt_icon":1},{"id":"2508454683","title":"MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2508454683","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508454683?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:51","pubTimestamp":1738677060,"startTime":"0","endTime":"0","summary":"Median overall survival  from THIO treatment extends to 16.9 months. CHICAGO, February 04, 2025----MAIA Biotechnology, Inc.,  , a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 pivotal Phase 2 clinical trial evaluating its lead clinical candidate, THIO, sequenced with Regeneron’s immune checkpoint inhibitor  cemiplimab  in patients with advanced non-small cell lung cancer  who failed two or more standard-of-care therapy regimens.THIO  is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer . Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine  induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. THIO-","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/maia-biotechnology-announces-positive-efficacy-135100694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","LU0058720904.USD","BK4588","LU1059921491.USD","IE00B7SZL793.SGD","BK4213","LU1261432733.SGD","LU0868494617.USD","CI","L","LU0053666078.USD","BK4157","BK4097","BK4585","IE00B19Z3B42.SGD","CPI","LU0289739699.SGD","BK4196","IE00B19Z4B17.USD","MAIA","IE00BSNM7G36.USD","IE00B19Z3581.USD","ORR","BK4107","IE0002270589.USD","IE00B66KJ199.SGD","OS","SOC","AEIS","IE0031619046.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":5,"totalSize":117,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{}}}